Filing Flows

Filing Flows › Xeris Biopharma Holdings (XERS) › Next earnings date

Xeris Biopharma Holdings (XERS) earnings: beat the estimate

Xeris Biopharma Holdings (XERS) reported on Nov 5, 2026 and beat the EPS estimate: $0.06 against $0.03 (+125.0%). Revenue was $107M for Q3 2026, +44% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+125.0% vs estimate
Beat rate60%

The last report

Xeris Biopharma Holdings reported revenue of $107M for the third quarter 2026 (+44% Y/Y), net earnings $11.3M: Product revenue, net $106M, Royalty, contract and other revenue $958K. How it makes money → · Every quarter →

Xeris Biopharma Holdings: EPS against the estimate, last 5 reportsXeris Biopharma Holdings: EPS against the estimate, last 5 reportsEstimateReported$0.00$0.00Nov 25$0.04$0.06Mar 26−$0.00$0.01May 26$0.00−$0.00Aug 26$0.03$0.06Nov 26
Latest (Nov 26): Estimate $0.03, Reported $0.06.

Xeris Biopharma Holdings' latest quarter

Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Xeris Biopharma Holdings beat earnings?

Xeris Biopharma Holdings (XERS) reported on Nov 5, 2026 and beat the EPS estimate: $0.06 against $0.03 (+125.0%).

When does XERS report earnings?

The next date is not set yet.

Does Xeris Biopharma Holdings usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.